Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07416552 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Not yet
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07416552: Clinical Trial Phase 1 study, sponsored by Hoffmann-La Roche.
NCT07416552 is a Phase 1 study that has not yet begun recruiting, run by Hoffmann-La Roche. The registered enrollment target is 180 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07416552, a Phase 1 study, has not yet begun recruiting, sponsored by Hoffmann-La Roche.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.
Interventions
- DRUG SPLIT Abs
- DRUG 203Pb-DOTAM
- DRUG 212Pb-DOTAM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2034-02-12 |
| Phase | Phase 1 |
What is known before NCT07416552 opens enrollment
NCT07416552 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (200% higher).
The record links to 0 conditions, and to 3 interventions - of which SPLIT Abs is the first listed.
NCT07416552 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07416552 about?
NCT07416552 is a clinical study titled "A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)". This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therap...
What is the current status of trial NCT07416552?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-07-31. Estimated completion is 2034-02-12.
What interventions are being tested in trial NCT07416552?
The interventions under investigation include: SPLIT Abs (DRUG), 203Pb-DOTAM (DRUG), 212Pb-DOTAM (DRUG).
Who is sponsoring clinical trial NCT07416552?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07416552's enrollment target sits among peer trials
180 299th of 2000 higher than 1,690 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI